Longitudinal 148-week Extension Study Of Anavex (R) 2-73 for the Treatment Of Alzheimer's Disease Demonstrates Maintained Activities of Daily Living Score (Adcs-adl) and Reduced Cognitive Decline (Mmse) For Patient Cohort on Higher Drug Concentration and Confirms Role of Precision Medicine Patient Selection Biomarkers